Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.41 |
| ▸ | HTR7 | P34969 | 6/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15184790 | 1.00 | PIK3CD (0.41) | PIK3CDHTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL15184736 | 0.85 | SMN1; SMN2 (0.41) | PIK3CDHTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL863488 | 0.84 | HTR7 (0.32) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL15184809 | 0.84 | HTR7 (0.32) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL717152 | 0.78 | PIK3CD (0.40) | PIK3CDHTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL864812 | 0.78 | TERT (0.38) | PIK3CDKCNH2TERT | |
| SCHEMBL863562 | 0.77 | HTR7 (0.43) | PIK3CDHTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL15184765 | 0.77 | HTR7 (0.43) | PIK3CDHTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL863598 | 0.77 | PIK3CD (0.35) | PIK3CDHTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL864109 | 0.76 | HTR7 (0.42) | PIK3CDHTR7ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885HTR7 1818/4885ADRA1D 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.